中国医科大学学报  2021, Vol. 50 Issue (11): 1031-1035, 1039

文章信息

李富顺, 陈静静, 田素飞, 孙国全, 褚云卓
LI Fushun, CHEN Jingjing, TIAN Sufei, SUN Guoquan, CHU Yunzhuo
2019年辽宁省33家医院血流感染病原菌及耐药率结果分析
Analysis of pathogens associated with bloodstream infections and their respective resistance patterns conducted in 33 hospitals in Liaoning Province during 2019
中国医科大学学报, 2021, 50(11): 1031-1035, 1039
Journal of China Medical University, 2021, 50(11): 1031-1035, 1039

文章历史

收稿日期:2020-12-30
网络出版时间:2021-11-03 17:55
2019年辽宁省33家医院血流感染病原菌及耐药率结果分析
中国医科大学附属第一医院检验科, 沈阳 110001
摘要目的 探讨2019年辽宁地区血流感染病原菌分布及其耐药情况。方法 选取辽宁省2019年1月至12月33家医院血培养分离株,按照全国细菌耐药监测网(CARSS)技术方案进行菌株鉴定及药物敏感性试验,采用Whonet 5.6软件对数据进行分析。结果 2019年共分离细菌6 584株,其中革兰氏阳性菌1 508株(占22.8%),革兰氏阴性菌5 082株(占77.2%),常见分离菌为大肠埃希菌、肺炎克雷伯菌、金黄色葡萄球菌、屎肠球菌和鲍曼不动杆菌。耐甲氧西林金黄色葡萄球菌(MRSA)检出率为18.4%。大肠埃希菌、肺炎克雷伯菌对三、四代头孢菌素耐药率分别为59.8%和44.9%,耐碳青霉烯大肠埃希菌、肺炎克雷伯菌的检出率分别为2.7%和12.9%。鲍曼不动杆菌对亚胺培南、美罗培南的耐药率分别为73.7%和71.6%。结论 辽宁地区血液中分离的病原菌存在不同程度耐药,应定期监测病原菌谱及耐药状况,为合理选用抗菌药物提供依据。
Analysis of pathogens associated with bloodstream infections and their respective resistance patterns conducted in 33 hospitals in Liaoning Province during 2019
Department of Laboratory Medicine, the First Hospital of China Medical University, Shenyang 110001, China
Abstract: Objective This article aims to explore pathogenic bacteria isolated from blood cultures and their drug resistance patterns in the Liaoning Province in 2019, which will improve understanding of the drug resistance of pathogens associated with bloodstream infections in this region. Methods The data of the strains isolated from the blood cultures was obtained from the Chinese Antimicrobial Resistance Monitoring System (CARSS) network in Liaoning Province between January 1 and December 31, 2019. Strain identification and drug susceptibility testing were conducted as per the CARSS network guidelines. Whonet 5.6 software was used to analyze the data. Results A total of 6 584 strains were isolated in 2019, of which 22.8% (1 508 strains) were Gram-positive and 77.2% (5 082 strains) were Gram-negative bacteria. The five most common isolates were Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Enterococcus faecium, and Acinetobacter baumannii. The MRSA isolation rate of Staphylococcus aureus was 18.4%. The resistance rates of Escherichia coli and Klebsiella pneumoniae to third and fourth generation cephalosporins were 59.8% and 44.9%, respectively. The detection rates of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae were 2.7% and 12.9%, respectively, and the resistance rates of Acinetobacter baumannii to imipenem and meropenem were 73.7% and 71.6%, respectively. Conclusion The bacteria isolated from blood cultures in this area exhibit varying degrees of resistance to antibacterial drugs. The spectrum of pathogenic bacteria and their resistance patterns should be monitored regularly in this area to provide a basis to allow rational selection of antibacterial drugs.

血流感染是一种严重性的全身感染性疾病,起病急、进展快、死亡率高[1],是欧洲和北美洲的七大死亡原因之一[2]。血流感染的监测有助于了解病原体的分布及其耐药性,对指导临床经验性治疗具有重要意义。不同地区血流感染的病原菌及耐药性不尽相同,研究[3]显示,血流感染首位病原体分别是大肠埃希菌和肺炎克雷伯菌。分析本省血流感染病原菌种类及其耐药模式,能够为血流感染治疗提供实验室数据,从而指导临床合理使用抗菌药物,降低血流感染死亡率及治疗费用。

1 材料与方法 1.1 研究对象

选取2019年1月1日至12月31日来自辽宁省参与全国细菌耐药监测网(China antimicrobial resistance surveillance system,CARSS)的33家国网单位血培养分离的病原菌,剔除单瓶阳性的凝固酶阴性葡萄球菌、草绿色链球菌及其他污染菌,同一患者重复菌株只保留第1株。

1.2 细菌鉴定及药敏试验

所有细菌鉴定及药敏试验均按照CARSS网技术方案(http://www.carss.cn)进行。细菌鉴定采用商品化检测系统如Vitek、Phoenix或MALDI-TOF。药敏试验采用纸片扩散法、自动化仪器法或Etest法。每周以金黄色葡萄球菌ATCC 29213、金黄色葡萄球菌ATCC25923、大肠埃希菌ATCC 25922、粪肠球菌ATCC 29212和铜绿假单胞菌ATCC 27853进行质量控制,若检测频率 < 1次/周,检测日需进行质量控制。

1.3 耐药菌确认

苯唑西林耐药或头孢西丁筛选试验阳性的金黄色葡萄球菌判定为耐甲氧西林金黄色葡萄球菌(methicillin-resistant Staphylococcus aureus,MRSA),敏感株则判定为甲氧西林敏感金黄色葡萄球菌(methicillin-sensitive Staphylococcus aureus,MSSA)。采用30 μg头孢西丁纸片于33~35 ℃孵育24 h,≤24 mm为甲氧西林(苯唑西林)耐药判定耐甲氧西林凝固酶阴性葡萄球菌(methicillin-resistant coagulase-negative Staphylococci,MRCNS),敏感株则判定为甲氧西林敏感凝固酶阴性葡萄球菌(methicillin- sensitive coagulase-negative Staphylococci,MSCNS)。耐万古霉素的肠球菌定义为万古霉素耐药的肠球菌(vancomycin-resistant Enterococcci,VRE)。碳青霉烯类耐药的肠杆菌科细菌(carbapenem-resistant-Enterobacteriaceae,CRE)指对亚胺培南、美罗培南或厄他培南中任一种药物耐药肠杆菌科细菌。

1.4 统计学分析

采用Whonet 5.6软件统计分析菌株分布及药物耐药率。采用2019年美国临床和实验室标准协会(clinical and laboratory standards institute,CLSI)药敏折点进行药敏试验的解释;替加环素采用美国食品药品监督管理局(Food and Drug Administration,FDA)折点[4];头孢哌酮/舒巴坦参考头孢哌酮折点;肺炎链球菌采用非脑膜炎折点分析。

2 结果 2.1 菌株分布

2019年辽宁省33家医院共分离6 584株细菌,其中,革兰氏阳性菌占22.8%(1 508株),革兰氏阴性菌占77.2%(5 082株)。大连地区、沈阳地区、辽南地区(营口、鞍山、丹东)、辽西地区(锦州、葫芦岛、阜新、盘锦)以及其他地区(本溪、抚顺、辽阳、铁岭)菌株分布存在统计学差异,见表 1

表 1 辽宁省33家医院血流感染病原体分布[n(%)] Tab.1 Distribution of isolates from pathogens associated with bloodstream infections in Liaoning Province[n (%)]
Organism All regions Dalian Shenyang Southern Liaoning Western Liaoning Other areas
Positive bacteria 1 505(22.9) 402(25.5) 610(28.8) 120(19.0) 156(14.1) 217(18.8)
  S. aureus 544(8.3) 160(10.1) 175(8.3) 52(8.2) 77(7.0) 80(6.9)
  E. faecium 339(5.1) 116(7.4) 150(7.1) 13(2.1) 26(2.4) 34(2.9)
  E. faecalis 186(2.8) 38(2.4) 92(4.3) 13(2.1) 12(1.1) 31(2.7)
  Coagulase negative staphylococci 106(1.6) 27(1.7) 49(2.3) 6(1.0) 11(1.0) 13(1.1)
  S. pneumoniae 79(1.2) 9(0.6) 39(1.8) 9(1.4) 6(0.5) 16(1.4)
  S. agalactiae 69(1.0) 10(0.6) 32(1.5) 10(1.6) 1(0.1) 16(1.4)
  Others 182(2.8) 42(2.7) 73(3.4) 17(2.7) 23(2.1) 27(2.3)
Negative bacteria 5 079(77.1) 1 175(74.5) 1 508(71.2) 511(81.0) 947(85.9) 938(81.2)
  E. coli 2 404(36.5) 495(31.4) 543(25.6) 292(46.3) 523(47.4) 551(47.7)
  K. pneumoniae 1 342(20.4) 345(21.9) 434(20.5) 108(17.1) 227(20.6) 228(19.7)
  A. baumannii 238(3.6) 88(5.6) 106(5.0) 13(2.1) 15(1.4) 16(1.4)
  P. aeruginosa 233(3.5) 67(4.2) 89(4.2) 20(3.2) 26(2.4) 31(2.7)
  E. cloacae 168(2.6) 35(2.2) 61(2.9) 9(1.4) 42(3.8) 21(1.8)
  Proteus sp. 76(1.2) 19(1.2) 21(1.0) 9(1.4) 14(1.3) 13(1.1)
  Serratia sp. 64(1.0) 12(0.8) 17(0.8) 17(2.7) 7(0.6) 10(0.9)
  Citrobacter sp. 61(0.9) 10(0.6) 18(0.8) 9(1.4) 16(1.5) 7(0.6)
  Salmonella sp. 54(0.8) 11(0.7) 23(1.1) 7(1.1) 7(0.6) 5(0.4)
  Others 439(6.7) 93(5.9) 196(9.3) 27(4.3) 70(6.3) 56(4.8)
Total 6 584(100) 1 577(100) 2 118(100) 631(100) 1 103(100) 1 155(100)

2.2 革兰氏阳性菌对抗菌药物的耐药情况

2.2.1 葡萄球菌属

金黄色葡萄球菌中MRSA检出率为18.4%(100/544)。除复方新诺明外,MRSA对抗菌药物的耐药率均高于MSSA。MRCNS分离率为72.2%(28/106),除四环素外,MRCNS对抗菌药物的耐药率均高于MSCNS。未分离到对万古霉素、利奈唑胺和替考拉宁耐药的葡萄球菌属,见表 2

表 2 葡萄球菌属细菌对抗菌药物耐药率和敏感率(%) Tab.2 Resistance rate of Staphylococcus to antimicrobial agents (%)
Antimicrobial agent MRSA(n = 100) MSSA(n = 444) MRCNS(n = 78) MSCNS(n = 28)
R S R S R S R S
Penicillin G 100.0 0 87.2 12.8 100.0 0 63.6 36.4
Erythromycin 88.9 9.1 71.7 27.2 88.8 11.2 64.3 32.1
Clindamycin 65.7 33.3 25.3 73.3 48.6 48.6 14.8 85.2
Ciprofloxacin 57.7 32.1 23.2 66.9 66.1 29.0 0 94.7
Levofloxacin 46.4 52.4 23.6 74.7 73.6 25.0 8.3 91.7
Tetracycline 44.9 55.1 9.9 88.6 22.4 77.6 25.0 75.0
Gentamicin 32.3 66.7 11.2 87.1 18.8 72.5 0.0 96.3
TMP-SMZ 15.3 84.7 21.2 78.8 62.3 37.7 30.8 69.2
Rifampicin 6.0 91.0 0.5 99.1 7.5 92.5 0 100.0
Linezolid 0 100.0 0 100.0 0 100.0 0 100.0
Vancomycin 0 100.0 0 100.0 0 100.0 0 100.0
Teicoplanin 0 100.0 0 100.0 0 100.0 0 100.0
Tigecycline 0 100.0 0 100.0 0 100.0 0 100.0

2.2.2 肠球菌属

肠球菌属常分离到屎肠球菌(59.2%)和粪肠球菌(32.5%)。屎肠球菌对青霉素类、大环内酯类、氟喹诺酮类耐药率 > 75%,高浓度链霉素及高浓度庆大霉素 > 30%;粪肠球菌对红霉素耐药率 > 50%。除四环素、高浓度链霉素外,屎肠球菌对大多数抗菌药物的耐药率高于粪肠球菌。分离1株屎肠球菌对万古霉素、利奈唑胺、替考拉宁耐药,及1株粪肠球菌对利奈唑胺耐药。见表 3

表 3 肠球菌属细菌对抗菌药物耐药率和敏感率(%) Tab.3 Resistance rate of Enterococcus to antimicrobial agents (%)
Antimicrobial agent Enterococcus faeciumn = 338) Enterococcus faecalisn = 186)
R S R S
Erythromycin 90.0 5.7 63.7 8.9
Penicillin G 85.5 14.5 5.4 94.6
Ampicillin 85.2 14.8 2.7 97.3
Ciprofloxacin 84.2 12.7 28.9 58.8
Levofloxacin 82.5 14.3 21.5 76.3
Rifampicin 61.6 30.3 35.4 47.9
Tetracycline 49.6 50.4 76.8 22.2
Streptomycin-high 38.1 61.9 30.7 69.3
Gentamicin-high 30.7 69.3 37.8 62.2
Teicoplanin 1.7 98.3 0 100.0
Vancomycin 1.5 98.5 0 100.0
Linezolid 0.3 98.2 0.6 93.8
Tigecycline 0 100.0 0 100.0

2.2.3 其他革兰氏阳性球菌

肺炎链球菌对大环内酯类抗菌药物耐药率 > 75%,复方新诺明耐药率为50%,对青霉素类抗菌药物、氯霉素、左氧氟沙星敏感率 > 90%。无乳链球菌对大环内酯类抗菌药物耐药率 > 75%,左氧氟沙星 > 50%,未发现对青霉素、头孢菌素及碳青霉烯类药物耐药的菌株。

2.3 革兰氏阴性菌对抗菌药物的耐药率

2.3.1 肠杆菌科细菌

大肠埃希菌对三、四代头孢菌素的耐药率为59.8%,且耐药株对氨基糖苷类、喹诺酮类耐药率高于敏感株,对替加环素的敏感性 > 99%。大肠埃希菌对碳青霉烯类抗菌药物的耐药率为2.7%,但存在地区差异,本溪、沈阳耐药率分别为3.8%和3.7%,大连为2.9%,而鞍山、葫芦岛、辽阳未发现耐药株。

肺炎克雷伯菌对三、四代头孢菌素的耐药率为44.9%,耐药株对所有监测药物耐药率明显高于敏感株。碳青霉烯耐药的肺炎克雷伯菌存在地区差异,大连和沈阳分别为28.4%和16.9%,而鞍山、葫芦岛、铁岭地区未检测到。其他肠杆菌科细菌耐药率见表 4

表 4 肠杆菌科细菌对抗菌药物耐药率和敏感率(%) Tab.4 Resistance rate of Enterobacteriaceae to antimicrobial agents (%)
Antimicrobial agent E. colin = 2 378) K. pneumoniaen = 1 324) E. cloacaen = 168) P. mirabilisn = 61) C. freudiin = 39) S. marcescensn = 58) Salmonella sp.(n = 64)
R S R S R S R S R S R S R S
Ampicillin 85.6 13.0 - - 91.2 5.9 50.9 45.6 82.1 14.3 86.2 3.4 71.2 28.8
Piperacillin 68.1 24.7 46.2 49.3 33.3 61.9 10.0 70.0 - - 12.5 87.5 - -
Cefazolin 67.5 32.5 46.9 53.1 95.3 4.7 43.1 56.9 90.3 9.7 100.0 0 8.0 92.0
TMP-SMZ 62.9 37.1 30.3 69.7 29.7 70.3 57.8 42.2 17.2 82.8 2.3 97.7 9.1 90.9
Ciprofloxacin 62.6 35.3 26.0 70.3 21.6 77.0 44.7 51.1 14.7 79.4 4.1 91.8 12.0 76.0
Cefuroxime 61.8 35.4 44.9 52.0 69.1 17.1 41.5 58.5 80.8 19.2 96.0 0 - -
ceftriaxone 59.8 39.9 42.2 57.6 50.5 46.8 38.9 61.1 58.6 37.9 13.6 84.1 5.3 94.7
Levofloxacin 58.5 38.1 21.6 75.7 14.4 81.4 32.8 63.9 18.4 78.9 1.8 94.6 2.6 56.4
Cefotaxime 58.1 41.7 30.9 68.9 49.4 49.4 34.5 65.5 52.0 44.0 21.9 78.1 0 100.0
Gentamicin 42.9 55.9 22.8 76.4 11.7 85.8 28.1 61.4 23.1 76.9 3.6 94.5 3.4 96.6
Aztreonam 41.9 50.8 28.8 67.2 39.6 57.7 12.5 83.9 44.4 52.8 7.3 90.9 7.9 92.1
Ampicillin-sulbactam 41.7 35.2 33.6 57.6 67.4 14.0 21.7 58.7 60.0 24.0 61.5 15.4 56.8 24.3
Cefepime 40.0 53.6 26.9 70.5 21.1 72.9 16.9 78.0 15.8 74.2 3.6 96.4 4.9 95.1
Ceftazidime 30.3 62.7 25.2 70.8 35.3 64.1 6.6 91.8 50.0 47.4 3.6 92.7 4.3 95.7
cefoxitin 9.9 82.2 20.4 76.0 97.1 2.9 2.5 97.5 81.8 13.6 57.9 26.3 - -
Cefoperazone-sulbactam 5.1 85.7 21.5 72.0 15.7 75.5 0 100.0 13.6 72.7 3.8 96.2 - -
Piperacillin-tazobactam 4.0 93.5 17.4 78.8 15.6 73.7 1.7 98.3 14.7 70.6 2.1 95.7 0 100.0
Ertapenem 2.7 97.2 12.7 87.1 9.3 88.8 2.6 97.4 8.0 92.0 2.9 97.1 - -
Imipenem 2.2 97.5 12.5 86.8 6.0 88.6 37.9 48.3 7.9 89.5 4.2 91.7 0 100.0
Meropenem 2.2 97.7 12.9 86.9 5.7 92.4 1.8 96.5 5.3 94.7 1.8 98.2 0 100.0
Amikacin 1.7 97.5 9.9 90.0 1.8 98.2 1.6 96.7 0 100.0 1.8 98.2 0 100.0
Tigecycline 0.1 99.1 1.7 88.0 2.5 87.5 - - 0 93.8 3.4 82.7 - -

2.3.2 非发酵革兰氏阴性杆菌

鲍曼不动杆菌对亚胺培南、美罗培南的耐药率分别为73.7%和71.6%,对头孢哌酮/舒巴坦耐药率 < 40%,除阿米卡星、左氧氟沙星和复方新诺明外,其他抗菌药物耐药率均 > 70%。铜绿假单胞菌对亚胺培南、美罗培南的耐药率分别为20.1%和18.1%,其他抗菌药物耐药率均 < 20%,其他非发酵菌耐药率见表 5

表 5 非发酵革兰氏阴性杆菌对抗菌药物耐药率和敏感率(%) Tab.5 Resistance rate of non-fermentative Gram negative bacteria to antimicrobial agents (%)
Antimicrobial agent A.baumanniin = 238) P.aeruginosan = 233) S.maltophilian = 40) B.cepacian = 23)
R S R S R S R S
Piperacillin 62.8 37.2 10.9 73.0 NA NA NA NA
Cefoperazone-sulbactam 38.5 37.3 9.7 77.4 NA NA NA NA
Ampicillin-sulbactam 70.7 25.0 NA NA NA NA NA NA
Piperacillin-tazobactam 70.5 28.7 5.6 81.4 NA NA NA NA
Ceftazidime 72.3 25.9 12.6 80.9 56.0 44.0 18.2 77.3
Ceftriaxone 77.4 11.6 NA NA NA NA NA NA
Cefotaxime 71.2 23.3 NA NA NA NA NA NA
Cefepime 73.8 24.5 10.9 80.9 NA NA NA NA
Aztreonam NA NA 18.1 66.4 NA NA NA NA
Imipenem 73.7 26.3 20.1 70.7 NA NA NA NA
Meropenem 71.6 28.4 18.1 77.0 NA NA 23.8 76.2
Amikacin 49.0 49.0 3.1 96.9 NA NA NA NA
Gentamicin 74.5 22.8 5.8 91.6 NA NA NA NA
Ciprofloxacin 73.6 26.4 11.7 83.5 NA NA NA NA
Levofloxacin 54.4 27.4 13.4 82.3 10.3 79.5 13.0 82.6
TMP-SMZ 50.3 49.7 NA NA 8.8 91.2 25.0 75.0

3 讨论

本研究共分离6 584株细菌,其中革兰氏阳性菌占22.81%,革兰氏阴性菌占77.19%。常见分离株为大肠埃希菌、肺炎克雷伯菌、金黄色葡萄球菌、屎肠球菌、鲍曼不动杆菌、铜绿假单胞菌,这与国内其他研究[5]常分离凝固酶阴性葡萄球不一致,可能与入选标准有关。

本研究结果显示,MRSA分离率为18.4%,低于中国细菌耐药监测网(China antimicrobial sureveillance network,CHINET)的31.7%[6]。MRSA和MSSA对左氧氟沙星的耐药率46.4%和23.6%均高于2018年CHINET监测数据的34%和11.9%,提示应慎重经验使用此类药物。本研究分离屎肠球菌多于粪肠球菌,且屎肠球菌的耐药率更高,与国内其他研究[7]一致。屎肠球菌对高浓度庆大霉素以及高浓度链霉素耐药率较低,提示可选取作用于细胞壁的敏感抗菌药物联合使用,提高杀菌作用。本研究分离到万古霉素、利奈唑胺、替考拉宁耐药的屎肠球菌,以及利奈唑胺耐药的粪肠球菌,此类耐药菌感染往往提示预后差,因此,医生应密切关注引起血流感染的肠球菌对糖肽类以及利奈唑胺的耐药情况。本研究结果显示,无乳链球菌对大环内酯类抗菌药物耐药率较高,这与大多数研究[8]一致,对青霉素及头孢菌素类抗菌药物有很高的敏感率,对非敏感菌株可进一步研究。对青霉素过敏的肺炎链球菌感染患者,大环内酯类抗菌药物可作为替代药物,但是研究显示其耐药率 > 90%,这与国内相关研究[9]一致,提示此类患者需采用更高等级的抗菌药。

本研究结果显示,血流感染以革兰氏阴性菌为主,特别是肠杆菌科细菌。本研究结果显示大肠埃希菌、肺炎克雷伯菌对三、四代头孢菌素耐药率分别为59.8%、44.9%,高于相关研究[10],此类耐药菌往往携带多种耐药基因,仅剩碳青霉烯类等少数抗菌药物具有活性。三、四代头孢菌素高耐药率及血流感染患者病情往往较重,导致临床常应用碳青霉烯类抗菌药物治疗这类细菌引起的感染,以致碳青霉烯类抗菌药物耐药率逐年升高,特别是肺炎克雷伯菌。本研究结果显示,大肠埃希菌、肺炎克雷伯菌对碳青霉烯类抗菌药物的耐药率分别为2.7%和12.7%,低于CHINET数据,而CRE菌株主要来自辽宁省几家大型三甲医院,可能与其收治疑难病症有关。本监测发现阴沟肠杆菌对碳青霉烯类抗菌药物的耐药率为9.3%,与2017年CHINET监测数据一致[11],提示需关注阴沟肠杆菌的耐药变化。本研究结果显示非发酵菌分离率较低,但是对大多数抗菌药物有较高的耐药率,碳青霉烯类抗菌药物耐药率 > 70%。国内相关研究[12]显示,鲍曼不动杆菌血流感染病死率为46.4%,多重耐药鲍曼不动杆菌菌血症死亡率甚至达到56.2%。本研究鲍曼不动杆菌仅对头孢哌酮/舒巴坦保持相对较高的敏感率,提示鲍曼不动杆菌菌血症应首选头孢哌酮/舒巴坦或与其他抗菌药物联合治疗。

综上所述,本省血流感染的病原菌分布及其耐药性存在地区差异,因此,应做好本地区耐药监测工作,定期发布结果,为临床抗感染治疗的经验用药、提高治愈率及减轻患者负担提供流行病学依据。

参考文献
[1]
TAXT AM, AVERSHINA E, FRYE SA, et al. Rapid identification of pathogens, antibiotic resistance genes and plasmids in blood cultures by nanopore sequencing[J]. Sci Rep, 2020, 10: 7622. DOI:10.1038/s41598-020-64616-x
[2]
PFALLER MA, CARVALHAES CG, SMITH CJ, et al. Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (2012-2017)[J]. Diagn Microbiol Infect Dis, 2020, 97(2): 115016. DOI:10.1016/j.diagmicrobio.2020.115016
[3]
TIAN L, SUN ZY, ZHANG Z. Antimicrobial resistance of pathogens causing nosocomial bloodstream infection in Hubei Province, China, from 2014 to 2016:a multicenter retrospective study[J]. BMC Public Health, 2018, 18(1): 1-8. DOI:10.1186/s12889-018-6013-5
[4]
王辉, 俞云松, 王明贵, 等. 替加环素体外药敏试验操作规程专家共识[J]. 中华检验医学杂志, 2013, 7(36): 584-587. DOI:10.3760/cma.j.issn.1009-9158.2013.07.004
[5]
张艳君, 马秀珍, 秦琴, 等. 血流感染病原菌的分布与耐药性分析[J]. 中国感染与化疗杂志, 2017, 17(3): 314-320. DOI:10.16718/j.1009-7708.2017.03.016
[6]
HU F, GUO Y, YANG Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(12): 2275-2281. DOI:10.1007/s10096-019-03673-1
[7]
王晓娟, 赵春江, 李荷楠, 等. 2011年、2013年和2016年医院内获得性血流感染常见病原菌分布及其耐药性分析[J]. 生物工程学报, 2018, 34(8): 1205-1217. DOI:10.13345/j.cjb.180192
[8]
FLAMM RK, SADER HS, FARRELL DJ, et al. Summary of ceftaroline activity against pathogens in the United States, 2010:report from the assessing worldwide antimicrobial resistance evaluation (AWARE) surveillance program[J]. Antimicrob Agents Chemother, 2012, 56(6): 2933-2940. DOI:10.1128/aac.00330-12
[9]
杨晶, 喻茹, 宋庆, 等. 肺炎链球菌血流感染患儿的临床特点与生存状况研究[J]. 中华医院感染学杂志, 2019, 29(14): 2216-2219.
[10]
HUANG C, SHI Q, ZHENG B, et al. Simulating moxalactam dosage for extended-spectrum β-lactamase-producing Enterobacteriaceae using blood antimicrobial surveillance network data[J]. Infect Drug Resist, 2019, 12: 1199-1208. DOI:10.2147/idr.s193712
[11]
CAI YM, CHEN C, ZHAO M, et al. High prevalence of metallo-β-lactamase-producing Enterobacter cloacae from three tertiary hospitals in China[J]. Front Microbiol, 2019, 10: 1610. DOI:10.3389/fmicb.2019.01610
[12]
ZHOU H, YAO YK, ZHU BQ, et al. Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: a retrospective study from a Chinese hospital[J]. Medicine, 2019, 98(13): e14937. DOI:10.1097/MD.0000000000014937